AMENDMENT NO. 2 TO THE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • February 24th, 2011 • Human Genome Sciences Inc • Biological products, (no disgnostic substances) • Delaware
THIS AMENDMENT NO. 2 TO THE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is made and entered into as of the 5th day of October 2010 (the “Effective Date”) by and between GLAXO GROUP LIMITED, a company organized under the laws of England and Wales with its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”) and HUMAN GENOME SCIENCES, INC., a Delaware corporation with its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”). GSK and HGS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT No. 1Co-Development and Commercialization Agreement • February 24th, 2011 • Human Genome Sciences Inc • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”) is entered into as of the 25th day of November, 2009 (“Amendment No. 1 Date”) by and among Human Genome Sciences, Inc., a Delaware corporation having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”) and Glaxo Group Limited, a company organized under the laws of England and Wales with its principal place of business at GlaxoWellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). HGS and GSK are hereinafter individually referred to as a “Party” and collectively as the “Parties.”
